Immunovant, Inc.
IMVT
$31.45
-$0.16-0.51%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -22.17% | -21.29% | -43.86% | -64.12% | -59.58% |
| Total Depreciation and Amortization | 8.49% | 27.11% | 44.33% | 56.59% | 63.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.50% | 17.81% | 18.46% | 21.98% | 17.45% |
| Change in Net Operating Assets | 449.63% | -261.21% | -600.87% | -59.57% | -557.10% |
| Cash from Operations | -8.36% | -30.15% | -58.65% | -71.60% | -75.46% |
| Capital Expenditure | 98.95% | 71.61% | 42.19% | -16.10% | -110.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 98.95% | 71.61% | 42.19% | -16.10% | -110.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 31.10% | 19,137.47% | 0.44% | -4.43% | -4.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -57.99% | -- | 94.69% | 94.69% | 94.69% |
| Cash from Financing | 31.08% | 19,120.79% | 1.65% | -3.28% | -3.80% |
| Foreign Exchange rate Adjustments | -140.03% | -94.93% | -112.95% | -111.20% | -24.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 139.34% | 296.00% | -75.90% | -83.09% | -69.63% |